Table 1

Efficacy and adherence rates across PrEP trials
Study [reference]: countries Population n Efficacy Lower bound of 95% CI Adherencea
Partners PrEP [8]: Kenya, Uganda Heterosexual couples 4758 67% TDF; 75% TDF/FTC 44% TDF; 55% TDF/FTC 82%
TDF2 Study [9]: Botswana Young men and women 1219 62% TDF/FTC 21.5% 80%
Bangkok TDF [12]: Thailand IVDU 2413 49% TDF 9.6% 67%
iPrEx [7]: S. America, SA, Thailand, USA MSM 2499 44% TDF/FTC 15% 51%
FEM-PrEP [10]: Kenya, SA, Tanzania Young women 2120 6% TDF/FTC −52% 37%
VOICE [11]: South Africa, Uganda, Zimbabwe Young women 5029 −49% TDF; - 4% TDF/FTC −130% TDF; −50% TDF/FTC 30%

Abbreviations: FTC, emtricitabine; IVDU, intravenous drug users; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; SA, South Africa; TDF, tenofovir disoproxil fumarate.

aAdherence was assessed by the proportion of participants with drugs detectable in plasma and who remained free of infection in the active PrEP arms.

Molina et al.

Molina et al. BMC Medicine 2013 11:186   doi:10.1186/1741-7015-11-186

Open Data